Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorescent sentinel lymph node identification in colon carcinoma using intravenous bevacizumab-800CW
2021-006796-41Phase 2Active
- Sponsor
- Meander Medical Center
- Start
- Jul 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab-IRDye800CW in colon cancer, sponsored by Meander Medical Center. Primary endpoint: Identification rate of sentinel lymph node with bevacizumab-800CW. Started Jul 2022; status: active.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2021-006796-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006796-41.